English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
CML Publications 2020
| Clinical Publications | Scientific Publications |
| December 2020 | |
| TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukemia Claudiani S et al. Br J Haematol, December 2020 (epub ahead of print) |
Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission Vigón L et al. J Clin Med, December 2020 – open access publication |
| Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom? Atallah E and Schiffer CA. Haematologica, December 2020 – open access publication |
Targeting of the Alox12-12-HETE in blast crisis chronic myeloid leukemia inhibits leukemia stem/progenitor cell function (Gao S et al. Cancer Manag Res, December 2020) – open access publication |
|
Why is it critical to achieve a deep molecular remission in chronic myeloid leukemia? |
Inhibitors targeting STAT5 signaling in myeloid leukemias: New Tetrahydroquinoline derivates with improved antileukemic potential (Prié G et al. ChemMedChem, December 2020) |
| BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analysed by NGS (Soverini S et al. Leukemia, December 2020) (epub ahead of print) |
Let-7b regulates the Adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells (Zhou X etc. Leuk Lymphoma, December 2020) |
| First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic-phase chronic myeloid leukemia (Oehler VG. Hematology Am Soc Hematol Educ Program, December 2020) – open access publication |
Evidence that knock down of GSK-3beta in chronic myelogenous leukemia cells augments IFN-gamma-induced apoptosis (Kauffmann MR et al. Leuk Res, December 2020) |
| Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice (Breccia M et al. Expert Rev Hematol, December 2020) |
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis (Tanabe Y et al. Blood Adv, December 2020) – open access publication |
| Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response (Pagnano KBB et al. Am J Hematol, December 2020) – open access publication |
Novel strategies to eradicate resistant cells in chronic myeloid leukemia |
|
Management of chronic myeloid leukemia during pregnancy among patients with tyrosine kinase inhibitor: |
Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients (Schmitz U et al. Cancers (Basel), December 2020) – open access publication |
|
Quality of life and symptom burden with first- and second generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia |
Circadian clock gene Period2 suppresses human chronic myeloid leukemia cell proliferation (Wang N et al. Exp Ther Med, December 2020) – open access publication |
|
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients |
|
|
Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for CML: |
|
|
Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era |
|
| November 2020 | |
| How to manage CML patients with comorbidities (Cortes J. Blood, November 2020) – open access publication |
Characterization of p190 BCR-ABL chronic myeloid leukemia reveals specific signalling pathways and therapeutic targets (Adnan-Awad S et al. Leukemia, November 2020) (epub ahead of print) |
| Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia (Abaza Y et al. Am J Hematol, November 2020) |
P19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signalling pathway in CML (Kuang Y et al. Blood Cells Mol Dis, November 2020) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: Updates from the LAST study on patient-reported outcomes and biomarkers for relapse (Braun TP and Druker BJ. JAMA Oncol, November 2020) |
AMD1 is required for the maintenance of leukemia stem cells and promotes chronic myeloid leukemic growth (Sari IN et al. Oncogene, November 2020) (epub ahead of print) |
| The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes (Sasaki K et al. Am J Hematol, November 2020) (epub ahead of print) |
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase (Manley PW et al. Leuk Res, November 2020) |
| Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial (Atallah E et al. JAMA Oncol, November 2020) (epub ahead of print) |
|
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: update form the LAST study on patient-reported outcomes and biomarkers for relapse (Braun TP and Druker BJ. JAMA Oncol, November 2020) (epub ahead of print) |
|
| Handling challenging questions in the management of chronic myeloid leukemia: When is it safe to stop tyrosine kinase inhibitors? (Rea D. Blood Adv, November 2020) – open access publication |
|
| Increased tumor burden in patients with CML after 36 months of imatinib discontinuation (Diral E et al. Blood, November 2020) |
|
| There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge (Ross DM and Hughes TP. Br J Haematol, November 2020) (epub ahead of print) |
|
| Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia (Efficace F et al. Leuk Lymphoma, November 2020) (epub ahead of print) |
|
| Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia (Clark SE et al. J Oncol Pharm Pract, November 2020) (epub ahead of print) |
|
|
Standardization of BCR-ABL1 p210 monitoring: From nested to digital PCR |
|
| Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukemia? (Gale RP and Saglio G. Br J Haematol, November 2020) (epub ahead of print) |
|
| A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation (Dragani M et al. J Clin Med, November 2020) – open access publication |
|
| Tyrosine kinase inhibitor treatment discontinuation in CML: patient views (Tromp VNMF et al. Leuk Lymphoma, November 2020) (epub ahead of print) – open access publication |
|
| October 2020 | |
| Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence and recommendations (Abruzzese E et al. Ther Adv Hematol, October 2020) - open access publication |
Recent advances in BCR-ABL tyrosine kinase inhibitors for overriding T315I mutation (Liu J et al. Chem Biol Drug Des, October 2020) (epub ahead of print) |
| Comparison of droplet digital PCR versus qPCR measurements on the International Scale for the molecular monitoring of chronic myeloid leukemia patients (Cortés AA et al. Mol Diagn Thera, October 2020) |
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem cell and progenitor cells in AML and CML (Herrmann H et al. Blood Adv October 2020) – open access publication |
| The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with CML in a practice-based cohort (Sato E et al. Cancer Med, October 2020) (epub ahead of print) - open access publication |
Increased expression of TIGIT/CD57 in peripheral blood/bone marrow NK cells in patients with chronic myeloid leukemia (Yao D et al. Biomed Res Int, October 2020) – open access publication |
| Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? (Atallah E and Schiffer CA. Haematologica, October 2020) – open access publication |
AMP-activated protein kinase activation primes cytoplasmic translocation and authophagic degradation of the BCR-ABL protein in CML cells (Koyama D et al. Cancer Sci, October 2020) (epub ahead of print) – open access publication |
| Chronic myeloid leukemia, Version 2.2021, NCCN Clinical Practice Guidelines (Deininger MW et al. J Natl. Compr Canc Netw, October 2020) – open access publication |
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features (Tusa I et al. Target Oncol, October 2020) – open access publication |
| Chronic myeloid leukemia in solid organ transplant patients: a case series (Amitai I et al. Int J Hematol, October 2020) (epub ahead of print) |
PD-1 expressing CD56-negative NK cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment (Ishiyama KI et al. Cancer Sci, October 2020) (epub ahead of print) – open access publication |
| Treatment outcomes in chronic myeloid leukemia: Does one size fit all? (Garcia-Horton A and Lipton JH. J Natl Compr Canc Netw, October 2020) – open access publication |
CytoGPS: A large-scale karyotype analysis of CML data (Abrams ZB et al. Cancer Genet, October 2020) (epub ahead of print) |
| Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib (Mulas O et al. Hematol Oncol, October 2020) |
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signalling complex (Gregor T et al. Cell Mol Sci, October 2020) |
| On the road to treatment-free remission in chronic myeloid leukemia: What about ‘the others’? (Stagno F et al. Expert Rev Anticancer Ther, October 2020) (epub ahead of print) |
DYRK2 controls a key regulatory network in chronic myeloid leukemia (Park CS and Lacorazza HD. Exp Mol Med, October 2020) (epub ahead of print) - open access publication |
| Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes (Cohen J et al. Leuk Lymphoma, October 2020) |
Detection of residual disease in CML utilizing genome next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow/stem progenitors (Karigane D et al. Leuk Lymphoma, October 2020) (epub head of print) |
| Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favourable in daily clinical practice (Zackova D et al. Leuk Lymphoma, October 2020) (epub ahead of print) |
Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine model marrow transplantation of CML (Ciccarelli BT et al. Leuk Res, October 2020) |
| September 2020 | |
| Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? (Branford S. Haematologica, September 2020) – open access publication |
CML – Not only BCR-ABL1 matters (Rinke J et al. Best Pract Res Clin Haematol, September 2020) |
| Breakpoints mapping of a t(9;22;12) chronic myeloid leukemia patient with e14a3 BCR-ABL1 transcript using nanopore sequencing (Zhao H et al. J Gene Med, September 2020) (epub ahead of print) |
Declaration of BCR-ABL1 independence (Zhao H and Deininger MW. Leukemia, September 2020) |
| Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia (Shanmunagathan N et al. Blood, September 2020) (epub ahead of print) |
Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells (Tanaka Y et al. Exp Hematol, September 2020) |
| Incidence of deep molecular responses and treatment-free remission in de novo CP-CMO patients (Etienne G et al. Cancers(Basel), September 2020) – open access publication |
Checkpoint kinase-1 inhibitors and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologenous recombination DNA damage repair (Fan Z et al. Oncol Rep, September 2020) (epub ahead of print) - open access publication |
| Erythropoietin treatment in chronic myeloid leukemia patients treated with frontline imatinib who developed anaemia (Cesini L et al. Eur J Hematol, September 2020) |
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor chronic myeloid leukemia cells (He B et al. Biomed Pharmacother, September 2020) – open access publication |
| Treatment-free remission in chronic myeloid leukemia harbouring atypical BCR-ABL1 transcripts (Dragani M et al. Mediterr J Hematol Infect Dis, September 2020) – open access publication |
BCR-ABL allosteric inhibitors: Where we are and where we are going to (Carofiglio F et al. Molecules, September 2020) – open access publication |
| Unravelling surviving expression in chronic myeloid leukemia: Molecular interactions and clinical implications (Bernardo PS et al. Blood Rev, September 2020) |
|
| Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients (Markovic U et al. Anticancer Res, September 2020) |
|
| Impact of the BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia (Nachi M et al. Hematol Oncol Stem Cell Ther, September 2020) – open access publication |
|
| Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotonib (Boons CCLM et al. Eur J Pharmacol, September 2020) – open access publication |
|
| August 2020 | |
| Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years? (Yilmaz U & Eskazan AE. Expert Rev Hematol, August 2020) (epub ahead of print) - open access publication |
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem cell disorders (Kaiser A et al. Leukemia, August 2020 |
| A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5) – AGMT-CML1 (Heibl S et al. Hematol Oncol, August 2020) (epub ahead of print) |
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses (Adnan Awad S et al. Leukemia, August 2020) (epub ahead of print) – open access publication |
| Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs (Sharf G et al. Leukemia, August 2020) – open access publication |
Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML (Toda J et al. Oncogene, August 2020) – open access publication |
| Low-dose tyrosine kinase inhibitors before treatment discontinuation do not repair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study (Cayassials E et al. Cancer, August 2020) – open access publication |
A high-content cytokine screen identifies myostatin propeptides as a positive regulator of primitive chronic myeloid leukemia cells (von Palffy S et al. Haematologica, August 2020) – open access publication |
| Epidural myeloid sarcoma a the presenting symptom of chronic myeloid leukemia blast crisis (Slouma M et al. Clin Rheumatol, August 2020) – open access publication |
Nuclear receptors as potential therapeutic targets for myeloid leukemia (Pan P & Chen X. Cells, August 2020) |
| Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT (He JB et l. Int J Cancer, August 2020) – open access publication |
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features (Tusa I et al. Target Oncol, August 2020) (epub ahead of print) – open access publication |
| Vascular events may predict the prognosis of patients with chronic myeloid leukemia (Ureshino H & Kamachi K. Int J Hematol, August 2020) – open access publication |
Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (Greiner L et al. Int J Cancer, August 2020) – open access publication |
| Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors (Lucijanic M & Krecak I. Int J Hematol, August 2020) – open access publication |
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis |
| Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study) (Genelli M et al. Blood Res, August 2020) (epub ahead of print) – open access publication |
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis (Liu J et al. Oncol Lett, August 2020) – open access publication |
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (Jyotsana N et al. Ann Hematol, August 2020) – open access publication |
|
| July 2020 | |
| A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukemia (Smith G et al. Br J Haematol, July 2020) (epub ahead of print) – open access publication |
PVR and ICAM-1 on blast crisis CML stem and progenitor cells with TKI resistance confer susceptibility to NK cells (Kim N et al. Cancers (Basel), July 2020) |
|
Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia |
Tyrosine kinase inhibitors induce alternative spliced BCR-ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR-ABL (Yuda J et al. Cancer Sci, July 2020) – open access publication |
| Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors (García-Gutiérrez V & Hernández-Boluda JCC. J Clin Med, July 2020) – open access publication |
Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors (Rothe K et al. Cell Stem Cells, July 2020) (epub ahead of print) |
| Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia (Ureshino H et al. Clin Lymphoma Myeloma Leuk, July 2020) (epub ahead of print) - open access publication |
Therapeutic inhibition of FcγRIIb signaling targets leukemia stem cells in chronic myeloid leukemia (Parting O et al. Leukemia, July 2020) (epub ahead of print) - open access publication |
| Comparison of BCR-ABL1 quantification in pheripheral blood and bone marrow using an International scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia (Greiner G et al. Clin Chem Lab Med, July 2020) – open access publication |
Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells (Hallal R et al. J Cell Mol Med, July 2020) (epub ahead of print) – open access publication |
| Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia (Abaza Y et al. Am J Hematol, July 2020) (epub ahead of print) |
Targeting SKP2/BCR-ABL pathway with Diosmetin suppresses chronic myeloid leukemia proliferation (Liu Y et al. Eur J Pharmacol, July 2020) (epub ahead of print) |
| Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity (Janssen L et al. Haematologica, July 2020) |
|
| Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission (Rousselot P et al. Blood Adv, July 2020) – open access publication |
|
| Another set of guidelines for chronic myeloid leukaemia (Clark RE. Br J Haematol, July 2020) (epub ahead of print) |
|
| Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML) (Turhan AG et al. Leuk Lymphoma, July 2020) |
|
| Platelet function in patients with chronic myeloid leukemia treated with asciminib (Nesr G et al. Leuk Lymphoma, July 2020) (epub ahead of print) |
|
| Timing for allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients (Hu B et al. Leuk Lymphoma, July 2020) (epub ahead of print) |
|
| June 2020 | |
| The EUTOS long-term survival (ELTS) score is superior to the Sokol score for predicting survival in chronic myeloid leukemia (Pfirrmann M et al. Leukemia, June 2020) (epub ahead of print) - open access publication |
An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia (Ko TK et al. Blood, June 2020) (epub ahead of print) |
| First-line imatinib vs second- and third-generation TKI’s for chronic phase CML: a systematic review and data analysis (Vener C et al. Blood Adv, June 2020) – open access publication |
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression (Sloma I et al. Haematologica, June 2020) (epub ahead of print) - open access publication |
| Influence of major BCR-ABL1 transcript subtype on outcomes in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib (Gentham A et al. Oncotarget, June 2020) – open access publication |
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitation and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia (Losson H et al. Pharmacol Res, June 2020) (epub ahead of print) |
| Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia (Annunziata M et al. Front Oncol, June 2020) – open access publication |
Micro RNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2 mediated autophagy (Li YL et al. Hum Cell, July 2020) |
| Chronic myeloid leukemia prognosis and therapy: Criticisms and perspectives (Russo D et al. J Clin Med, June 2020) – open access publication |
Inhibition of USP1, a new partner of BCR-ABL, results in decrease of BCR-ABL level in K562 cells (Antonenko SV et al. Exp Oncol June 2020) |
| Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (Hochhaus A et al. Leukemia, June 2020) (epub ahead of print) - open access publication |
Blastic transformation of BCR-ABL1 positive chronic myeloid leukemia through acquisition of CBFB-MYH11 and mutant KIT (Shoumariyeh K et al. B J Haematol, June 2020) (epub ahead of print) -open access publication |
| How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA) (Breccia M et al. Cancer Med, June 2020) – open access publication |
|
| Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia (Pagani IS et al. Leuk Lymphoma, June 2020) (epub ahead of print) |
|
| The clinical impact of time to response in de Novo accelerated-phase chronic myeloid leukemia (Ohanian M et al. Am J Hematol, June 2020) (epub ahead of print) |
|
| May 2020 | |
| Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors (Hochhaus A et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis (Tang Z et al. Mod Pathol, May 2020) (epub ahead of print) |
|
High-risk additional chromosomal abnormalities at low blast counts herald death by CML |
Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: Recent advances (Cumbo C et al. Cancer Manag Res, May 2020) – open access publication |
| Analysis of chronic myeloid leukemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission (Machova Polakova K et al. Leukemia, May 2020) (epub ahead of print) |
Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts (Petiti J et al. J Clin Med, May 2020) – open access publication |
| Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukemia (Kaur U et al. Br J Haematol, May 2020) (epub ahead of print) - open access publication |
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells (Lernoux M et al. Clin Epigenetics, May 2020) – open access publication |
| Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations (Claudiadini S et al. Haematologica, May 2020) (epub ahead of print) - open access publication |
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia (Joshi SK. Leukemia, May 2020) (epub ahead of print) - open access publication |
| Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years (Dulucq S et al. Br J Haematol, May 2020) – open access publication |
Coexistance of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in CML: A case report (Shi XB et al. World J Clin Cases, May 2020) – open access publication |
| Treatment-free remission in patients with chronic myeloid leukemia (Ross DM and Hughes TP. Nat Rev Clin Oncol, May 2020) (epub ahead of print) |
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (Yu C et al. Haematologica, May 2020) – open access publication |
| Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis (Wang Q et al. Leuk Lymphoma, May 2020) |
Recruiting TP53 to target chronic myeloid leukemia stem cells Grant S. Haematologica, May 2020 – open access publication http://www.haematologica.org/content/105/5/1172 |
| ABL genomic editing sufficiently abolished oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo (Chen SH et al. Cancers (Basel), May 2020) – open access publication |
|
| Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia (Ma CC et al. J Int Med Res, May 2020) – open access publication |
|
| High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Hehlmann R et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
|
| Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts (Petiti J et al. J Clin Med, May 2020) – open access publication |
|
| Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia (Kumar R et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
|
| Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis (Xiao FY et al. Life Sci, May 2020) – open access publication |
|
| Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia (MA CC et al. J Int Med Res, May 2020) – open access publication |
|
| April 2020 | |
| Response and resistance to BCR-ABL1-targeted therapies (Braun TP et al. Cancer Cell, April 2020) |
Nobiletin promotes megakaryocytic differentiation through the MAPK/ERK-dependent EGR1 expression and exerts anti-leukemic effects in human chronic myeloid leukemia (CML) K562 cells (Yen JH et al. Cells, April 2020) – open access publication |
| Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased killer cells (Irani YD et al. Br J Haemaol, April 2020) (epub ahead of print) – open access publication |
Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR-ABL/AKT/mTOR pathway (Zhang Z et al. Int J Mol Med, April 2020) |
| Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia (Brümmendorf TH et al. Ann Hematol, April 2020) (epub ahead of print) - open access publication |
Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukemia (Gong Z et al. Br J Haematol, April 2020) (epub ahead of print) - open access publication |
| Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias (Maiti A et al. Acta Haematol, April 2020) (epub ahead of print) |
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemia stem cells in CML (Lin H et al. Blood, April 2020) (epub ahead of print) |
| Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study (Cortes JE et al. Leukemia, April 2020) (epub ahead of print) – open access publication |
Response and resistance to BCR-ABL-1 targeted therapies (Braun TP et al. Cancer Cell, April 2020) |
| Metabolic analysis of patients with chronic myeloid leukemia and cardiovascular adverse events after treatment with tyrosine kinase inhibitors (Caocci et al. J Clin Med, April 2020) – open access publication |
GZD824 as a FLT3, FGFR1 and PDGFR-alpha inhibitor against leukemia in vitro and in vivo (Wang Y et al. Transl Oncol, April 2020) (epub ahead of print) - open access publication |
| Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring (Jabbour E and Kantarjian H. Am J Hematol, April 2020) (epub ahead of print) |
Basic knowledge on BCR-ABL1-positive extracellular vesicles (Jurj A et al. Biomark Med, April 2020) (epub ahead of print) |
| Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N-Road study (Nishiwaki K et al. Cancer Med, April 2020) (epub ahead of print) - open access publication |
Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients (Spiess D et al. Ann Hematol, April 2020) (epub ahead of print) – open access publication |
| The differentiated diagnosis of basophilia in patients undergoing BCR-ABL testing (Smith CJ et al. Am J Hematol, April 2020) (epub ahead of print) - open access publication |
A novel chimeric antigen receptor redirecting T-cell specificity towards CCD26+ cancer cells (Zhou S et al. Leukemia, April 2020) (epub ahead of print) |
| Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia (Hino M et al. Int J Hematol, April 2020) (epub ahead of print) |
TKIs induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL (Yuda J et al. Cancer Sci, April 2020) (epub ahead of print) - open access publication |
| How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis frontline monitoring registries of the Italian Medicines Agency (AIFA) (Breccia M et al. Cancer Med, April 2020) (epub ahead of print) - open access publication |
Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides (Yang H et al. Cancer Lett, April 2020) (epub ahead of print) |
| Synthesis and characterization of Telmisartan-derived cell death modulators to circumvent imatinib resistance in chronic myeloid leukemia (Gust R et al. ChemMedChem, April 2020) (epub ahead of print) - open access publication |
|
| Role of DNA damage response in suppressing malignant progression of chronic myeloid leukemia and Polycythemia Vera: Impact of different oncogenes (Stetka J et al. Cancers (Basel), April 2020) – open access publication |
|
| March 2020 | |
| TARGET: a survey of real-world management of chronic myeloid leukemia across 33 countries (Turkina A et al. Br J Haematol, March 2020) (epub ahead of publication) |
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse model (Zhang J et al. Br J Haematol, March 2020) (epub ahead of print) |
|
Risk stratification of chronic myeloid leukemia according to different prognostic scores |
An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia (Ko TH et al. Blood, March 2020) (epub ahead of print) |
| Patient-initiated discontinuation of tyrosine kinase inhibitor for chronic myeloid leukemia (Langabeer SE et al. Case Rep Hematol, March 2020) – open access publication |
Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and –resistant chronic myeloid leukemia cells (Jiang L et al. Eur J Pharmacol, March 2020) (epub ahead of print) – open access publication |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (Hochhaus A et al. Leukemia, March 2020) (epub ahead of print) – open access publication |
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells (Shibata N et al. Oncogene, March 2020) (epub ahead of print) |
| Pharmacokinetics of dasatinib in hemodialysis patient with chronic myeloid leukemia and chronic kidney disease (Mori J et al. Int J Hematol, March 2019) (epub ahead of print) |
SIRT7: an influence factor in healthy aging and the development of age-dependet myeloid stem cell disorders |
| Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the new TARGET study 2nd line (Sakurai M et al. Int J Hematol, March 2020) (epub ahead of print) |
Ponatinib induces vascular toxicity through the Notch-1 signaling pathway (Madonna R et al. J Clin Med, March 2020) – open access publication |
| The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data (Luciano L et al. Eur J Haematol, March 2020) (epub ahead of print)- open access publication |
Involvement of MCL-1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315l(+) Ph+leukemia cells (Inoue C et al. Biochem Biophys Res Commun, March 2020) (epub ahead of print) |
|
Novel therapeutic approaches in chronic myeloid leukemia |
|
|
Experience of living with chronic myeloid leukemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies |
|
|
BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia |
|
| Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia (Eskazan AE. Leukemia, March 2020) (epub ahead of print) |
|
| Does patient sex play a role in treatment-free remission in chronic myeoid leukemia? (Ureshino H et al. Int J Hematol, March 2020) (epub ahead of print) |
|
| Significance of lymphocyte count, monocyte count, and lymphocyte-to-monocyte ratio in predicting molecular response in patients with chronic myeloid leukemia: A single center experience (Pepedil-Tanrikulu F et al. Clin Lab, March 2020) |
|
| Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients (Koutake Y et al. Int J Hematol, March 2020) (epub ahead of print) |
|
| February 2020 | |
| Side-effect profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia (Chan O et al. Blood Adv, February 2020) – open access publication |
Phosphorylation-dependent differences in CXCR4-LASP-AKT1 interaction between breast cancer and chronic myeloid leukemia (Butt E et al. Cells, February 2020) – open access publication |
| Prospects of achieving treatment-free remission in chronic myeloid leukemia) (Saglio G et al. Br J Haematol, February 2020) (epub ahead of print) - open access publication |
Aberrant RAG-mediated recombination contributes in lymphoid blast crisis of chronic myeloid leukemia (Thomson DW et al. Leukemia, February 2020) (epub ahead of print) |
| Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the past ten years (Dulucq S et al. Br J Hematol, February 2020) (epub ahead of print) |
Model-based inference and classification of immunological control mechanism from TKI cessation and dose reduction in CML patients (Hähnel T et al. Cancer Res, February 2020) (epub ahead of print) |
| Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results analysis (Wang Q et al. Leuk Lymphoma, January 2020) (epub ahead of print) |
Comparison of BCR-ABL 1 quantification in peripheral blood and bone marrow using an international scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia (Greiner G et al. Clin Chem Lab Med, February 2020) (epub ahead of print) |
| Mechanisms of cardiovascular toxicity of BCR-ABL 1 tyrosine kinase inhibitors in chronic myelogenous leukemia (Gustafson D et al. Curr Hematol Rep, February 2020) (epub ahead of print) |
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia (Huang W et al. Leukemia, February 2020) (epub ahead of print) - open access publication |
| A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study (Etienne G et al. Br J Haematol, February 2020) (epub ahead of print) |
SRSF1 mediates cytokine induced impaired imatinib sensitivity in chronic myeloid leukemia (Sinnakannu JK et al. Leukemia, February 2020) (epub ahead of print) |
| Novel illumine-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia (Romzova M et al. Br J Hematol, February 2020) (epub ahead of print) |
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia (Adnan Awad S et al. Blood Adv, February 2020) – open access publication |
| What’s NEXT for CML-NGS mutation screening? (Shanmunagathan N et al. Blood, February 2020) |
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors |
| DNA damage and DNA damage response in chronic myeloid leukemia (Popp HD et al. Int J Mol Sci, February 2020) – open access publication |
|
|
Nanomaterials as magic bullets in the treatment of leukemia |
|
| January 2020 | |
| Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia (Masarova L et al. Cancer, January 2020) (epub ahead of print) |
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin SCT/TAL-1 – CD44 axis (Godavarthy PS et al. Haematologica, January 2020) – open access publication |
| Long-term results of frontline dasatinib in chronic myeloid leukemia (Maiti A et al. Cancer, January 2020) (epub ahead of print) |
How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study (Zhang H et al. J Biomol Strat Dyn January 2020) |
| Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation of CML (Gottschalk A et al. Blood, January 2020) (epub ahead of print) |
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukemia patients stopping tyrosine kinase inhibitor therapy |
A randomized phase II trial of hydroxychloroquine and imatinib alone for patients with chronic myeloid leukemia in major cytogenetic response with residual disease |
The leukemia stem cell: similarities, differences and clinical prospects in CML and AML (Vetrie D et al. Nat Rev Cancer, January 2020) (epub ahead of print) |
| Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, January 2020) |
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy (Kinstrie R et al. Leukemia, January 2020) (epub ahead of print) |
| What are the considerations for tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia? (Harrington P et al. Expert Rev Hematol, January 2020) (epub ahead of print) |
Knock-out of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance (Herrmann AD et al. J Cell Mol Med, January 2020) (epub ahead of print) – open access publication |
|
Successful planned pregnancy through vitrified-warmed embryo transfer in a women with chronic myeloid leukemia: Case report and literature review |
Defining the niche interactions to target chronic myeloid leukemia stem cells (Mitchell R et al. Haematologica, January 2020) – open access publication |
| Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS study of the Kanto CL Study Group (Yamaguchi H et al. Int J Hematol, January 2020) (epub ahead of print) |
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin – SCL/TAL1 – CD44 axis (Godavarthy PS et al. Haematologica, January 2020) – open access publication |
| Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells (Grandjenette C et al. Cancer Lett, January 2020) |
|
